An operation that targets the nerves connected to the kidney has been found to significantly reduce blood pressure in patients with hypertension, according to the results of a clinical trial led in the UK by Queen Mary University of London and Barts Health NHS Trust, and supported by the National Institute for Health Research (NIHR).
If the findings are confirmed in more extensive clinical trials, the surgery could offer hope to patients with high blood pressure who do not respond to drugs, and are at increased risk of cardiovascular diseases, including stroke and heart attack.
The international clinical trial, carried out from 2017 to 2018 at St Bartholomew’s Hospital in the UK by the NIHRBarts Biomedical Research Centre, tested a one-hour operation called ‘renal denervation’, which uses ultrasound energy to disrupt the nerves between the kidneys and the brain that carry signals for controlling blood pressure.
Significant reduction in blood pressure
146 patients in the United States, France, Germany, the Netherlands, Belgium and the United Kingdom were randomised to receive either renal denervation or a ‘sham procedure’ – the surgical equivalent of a placebo. Patients also remained off blood pressure medications for two months unless specified blood pressure levels were exceeded.
After two months, the renal denervation group experienced an 8.5 mm Hg reduction in blood pressure, which was a 6.3 mm Hg greater reduction compared with the sham group.
More than 66 per cent of subjects treated with renal denervation demonstrated a 5 mm Hg or greater reduction in blood pressure, compared with 33 per cent in the sham group.
No major adverse events were reported in either group, and the blood pressure lowering effect of renal denervation was consistent across sex and ethnicity.
An alternative to lifelong medications
UK Principal Investigator Dr Melvin Lobo from Queen Mary’s William Harvey Research Institute and Barts Health NHS Trust said: “These results leave us clinicians in no doubt that this ultrasound-based therapy works to improve blood pressure control – at least in the short term. Further larger trials will be needed to confirm the efficacy and safety of the technology, but we hope that they could lead to renal denervation therapy being offered as an alternative to lifelong medications for hypertension.”
The study has limitations including the short follow-up time of two months. This was done for safety reasons to minimise the duration of patients being off antihypertensive medications. Longer follow-up of this trial and additional numbers of treated patients will be necessary to provide greater assurance of safety and to exclude rare adverse events.
Receive an email update when we add a new HYPERTENSION article.
The Latest on: Hypertension
via Google News
The Latest on: Hypertension
- Hypertension Management Devices Market Set for Rapid Growth During by 2024 on February 19, 2019 at 6:56 am
Feb 19, 2019 (Heraldkeeper via COMTEX) -- New York, February 19, 2019: The scope of the report includes a detailed study of Hypertension Management Devices Market with the reasons given for variations ... […]
- Hemodialysis Market to Reach $99.74 Billion by 2025: Allied Market Research on February 19, 2019 at 3:42 am
Surge in funding for improved products & services, rise in number of ESRD patients, and increase in incidence of hypertension and diabetes drive the growth in the global hemodialysis market. […]
- High blood pressure - the 2p a day supplements to prevent deadly hypertension symptoms on February 18, 2019 at 8:00 pm
High blood pressure is a deadly condition that affects more than 25 per cent of all adults in the UK. The condition, which is also known as hypertension, puts extra stress on blood vessels and vital o... […]
- Clinician Communication Key for Hypertension Control on February 18, 2019 at 6:39 am
Successful management of chronic conditions such as hypertension may depend on the clinician's ability to engage patients and build relationships with them, a study found. In a survey of providers wor... […]
- Hypertension: a silent killer on February 17, 2019 at 2:47 pm
Blood pressure (BP) is the pressure or force of blood against the walls of the blood vessels (arteries) as it circulates throughout the body. Hypertension is characterised by high arterial pressure, t... […]
- Conatus And Emricasan In NASH Cirrhotic Portal Hypertension: The Update on February 15, 2019 at 12:14 pm
Portal hypertension is elevated blood pressure in the portal vein. There are no FDA-approved treatments and mainstay therapies have achieved limited success. The data readout from the 24 week ... […]
- How to manage hypertension on February 15, 2019 at 8:11 am
Your circulatory system works hard, constantly getting freshly oxygenated blood from your heart to your tissues and organs. If you don't take care of it, it cannot perform at its peak. In an average h... […]
- How effective is grocery-store based nutrition education for treating hypertension? on February 14, 2019 at 9:05 am
Offering on-site nutrition services such as access to registered dietitians is becoming more common place in grocery stores, but does it make shoppers with chronic illnesses such as hypertension make ... […]
- Guidelines Updated for Pulmonary Arterial Hypertension in Adults on February 14, 2019 at 3:04 am
(HealthDay News) -- In the latest evidence-based guideline from the American College of Chest Physicians, published online in CHEST, updated recommendations are provided for the management of adults w... […]
via Bing News